Abstract
Hypertension is associated with the flow of blood under high pressures, yet the complications of hypertension, such as myocardial infarction or stroke are paradoxically thrombotic rather than haemorrhagic. This could be explained by increasing evidence which suggests that hypertension fulfils the pre-requisites of the Virchows triad for thrombogenesis, leading to a prothrombotic or hypercoagulable state. Hypertension leads to changes in the platelets, endothelium and the coagulation and fibrinolytic pathways which help to promote the induction and the maintenance of this prothrombotic state. These changes can to a certain extent be reversed by the treatment of hypertension, although different antihypertensive agents may have variable effects in reversing these changes. Some of the effects may be simply related to normalisation of blood pressure, but certain groups of drugs such as those acting on the renin-angiotensin-aldosterone system appear to have an effect over and above this. Anti-platelet agents have also been shown to confer a degree of benefit to ‘high risk’ hypertensive patients. The study of the prothrombotic state in hypertension is therefore of paramount importance, as understanding the pathogenic processes underlying it can help prevent many of the complications associated with this condition.
Keywords: hypertension, thrombosis, antihypertensive agents, antiplatelet agents, platelet activation, endothelial dysfunction
Current Pharmaceutical Design
Title: The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Volume: 9 Issue: 21
Author(s): Sunil Nadar and Gregory Y.H. Lip
Affiliation:
Keywords: hypertension, thrombosis, antihypertensive agents, antiplatelet agents, platelet activation, endothelial dysfunction
Abstract: Hypertension is associated with the flow of blood under high pressures, yet the complications of hypertension, such as myocardial infarction or stroke are paradoxically thrombotic rather than haemorrhagic. This could be explained by increasing evidence which suggests that hypertension fulfils the pre-requisites of the Virchows triad for thrombogenesis, leading to a prothrombotic or hypercoagulable state. Hypertension leads to changes in the platelets, endothelium and the coagulation and fibrinolytic pathways which help to promote the induction and the maintenance of this prothrombotic state. These changes can to a certain extent be reversed by the treatment of hypertension, although different antihypertensive agents may have variable effects in reversing these changes. Some of the effects may be simply related to normalisation of blood pressure, but certain groups of drugs such as those acting on the renin-angiotensin-aldosterone system appear to have an effect over and above this. Anti-platelet agents have also been shown to confer a degree of benefit to ‘high risk’ hypertensive patients. The study of the prothrombotic state in hypertension is therefore of paramount importance, as understanding the pathogenic processes underlying it can help prevent many of the complications associated with this condition.
Export Options
About this article
Cite this article as:
Nadar Sunil and Lip Y.H. Gregory, The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment, Current Pharmaceutical Design 2003; 9 (21) . https://dx.doi.org/10.2174/1381612033454559
DOI https://dx.doi.org/10.2174/1381612033454559 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of an Angiotensin II Receptor Blocker and Two Angiotensin Converting Enzyme Inhibitors on Transforming Growth Factor-β (TGF-β) and α-Actomyosin (α SMA), Important Mediators of Radiation-Induced Pneumopathy and Lung Fibrosis
Current Pharmaceutical Design Substance Abuse and Movement Disorders
Current Drug Abuse Reviews Chemistry and Pharmacological Properties of Some Natural and Synthetic Antioxidants for Heavy Metal Toxicity
Current Medicinal Chemistry Moderate Hypothermia in the Management of Severe Traumatic Brain Injury: A Good Idea Proved Ineffective?
Current Pharmaceutical Design Inflammation: A Link Between Hypertension and Atherosclerosis
Current Hypertension Reviews Therapeutical Relevance of MAP-Kinase Inhibitors in Renal Diseases: Current Knowledge and Future Clinical Perspectives
Current Medicinal Chemistry Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Use of Double-source Computed Tomography for Evaluation of the Relationship Between Smoking and Coronary Plaques
Current Medical Imaging The Role of Pericytes in Blood-Brain Barrier Function and Stroke
Current Pharmaceutical Design Comparison between Two Calcium Antagonists: Blood Pressure Reduction and Renal Effects in Hypertensive Patients with Type 2 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Axitinib in the Treatment of Head and Neck Malignancies
Current Clinical Pharmacology Impact of Novel Screening Technologies on Ion Channel Drug Discovery
Combinatorial Chemistry & High Throughput Screening Calcium Channel Subtypes and Exocytosis in Chromaffin Cells at Early Life
Current Molecular Pharmacology Ligands of Diltiazem Binding Site: An Overview of Some Chemotypes
Mini-Reviews in Medicinal Chemistry The Relevance of Long-Term Adherence to Non-Pharmacological and Pharmacological Treatment of Hypertension
Current Hypertension Reviews Beta-Blockers: Current State of Knowledge and Perspectives
Mini-Reviews in Medicinal Chemistry Roles of SM22α in Cellular Plasticity and Vascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Cholesterol Absorption Blockade with Ezetimibe
Current Drug Targets - Cardiovascular & Hematological Disorders Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets